1. Home
  2. SEE vs IMVT Comparison

SEE vs IMVT Comparison

Compare SEE & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sealed Air Corporation

SEE

Sealed Air Corporation

HOLD

Current Price

$41.84

Market Cap

5.1B

Sector

Industrials

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$27.48

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEE
IMVT
Founded
1960
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
5.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SEE
IMVT
Price
$41.84
$27.48
Analyst Decision
Buy
Buy
Analyst Count
11
9
Target Price
$43.50
$29.13
AVG Volume (30 Days)
3.0M
1.5M
Earning Date
03-02-2026
02-06-2026
Dividend Yield
1.91%
N/A
EPS Growth
13.73
N/A
EPS
3.09
N/A
Revenue
$5,331,600,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.16
N/A
P/E Ratio
$13.54
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.78
$12.72
52 Week High
$44.27
$27.80

Technical Indicators

Market Signals
Indicator
SEE
IMVT
Relative Strength Index (RSI) 57.26 58.35
Support Level $41.75 $23.90
Resistance Level $41.91 $26.82
Average True Range (ATR) 0.10 1.27
MACD -0.03 -0.01
Stochastic Oscillator 43.33 85.63

Price Performance

Historical Comparison
SEE
IMVT

About SEE Sealed Air Corporation

Sealed Air is organized via two reporting segments. Food includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Protective includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: